

# Statens Serum Institute discuss Maintenance of T Cell Memory by Liposomes at Cancer Vaccines 2015

*SMI's Cancer Vaccines conference will be taking place on the 16th – 17th September 2015 at the Marriott Regents Park Hotel in London, UK.*

LONDON, ENGLAND, UNITED KINGDOM, August 26, 2015 /EINPresswire.com/ -- SMI are thrilled to announce that the Director from the Department of Infectious Disease & Immunology at Statens Serum Institut, has joined the agenda for its 4th annual [Cancer Vaccines conference](#). Taking place in just 3 weeks' time, the scientifically sound event on cancer immunotherapy has attracted a global audience of market leaders and scientific pioneers to explore the latest developments in new treatments and combination therapies.

With an emphasis on immuno-oncology, this year's event will feature case studies led by major pharmaceutical

organisations and will provide strategic guidance on tumour prevention, analyse biomarkers and diagnostic tools, discuss fully personalised cancer treatments and explore multi-modal cancer immunotherapy.

Led by Northwest Biotherapeutics, BioNTech RNA Pharmaceuticals, The National Cancer Institute and Kings College London, delegates will also be able to join panel debates to discuss the future of cancer vaccines with a focus on achieving sustained antitumor immune response.

Those who have confirmed attendance include: INSERM, UCLH BioResources, UCL Cancer Institute, Bavarian Nordic, Barts Cancer Institute, Exicure, Barts Cancer Institute, Bavarian Nordic, Biosafe Sa, Boehringer Ingelheim, Cancer Research UK, Cancer Vaccines Ltd, DanDrit Biotech, Exicure, Immunicum, INSERM, IntelliCyt, Nottingham Trent University, Plymouth University, Shionogi, St Georges Hospital Medical School, Statens Serum Institute, THERAVECTYS, TRON Translational Oncology Mainz, UCL Cancer Institute, UCLH BioResources, University Of Southampton.

Featured Speakers Include:

- Professor Farzin Farzaneh, Professor of Molecular Medicine, Kings College London
- Thomas Felzmann, CEO, Activartis
- Michael Hanna, Chairman and CEO, Vaccinogen
- Sebastian Kreiter, VP Immunotherapy, BioNTech RNA Pharmaceuticals
- Vaios Karanikas, Biomarker & Experimental Medicine Leader, Tumor Immunology, Roche
- Linda Powers, CEO, Northwest Biotherapeutics



- Ravi A. Madan, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute
- Graham Pockley, Professor of Immunobiology and Associate Director, John van Geest Cancer Research Centre (JvGCRC). Nottingham Trent University
- Professor Dr. Dirk Jager, Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg

Featured content such as interviews with some of the key speakers is available to read online in the event download centre.

For further details or to view a programme for the show, visit the [website](#)

Cancer Vaccines

16th - 17th September 2015

Marriott Regents Park, London UK

[www.cancervaccineevent.com](http://www.cancervaccineevent.com)

Sponsored by Northwest Biotherapeutics and Intellicyt

--- END ---

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Teri Arri

SMi Group Ltd

+44 (0)20 7827 6162

email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2015 IPD Group, Inc. All Right Reserved.